drug companies

Drug prices are too high. What is Congress trying to do about it?

Chairman Charles E. Grassley, right, and ranking member Sen. Ron Wyden are seen before a Senate Finance Committee on drug pricing in America on February 26, 2019. (Tom Williams/CQ Roll Call)

Both the House and the Senate have competing bills aimed at addressing the rising costs of prescription drugs, a legislative priority backed by President Donald Trump.

The new way prosecutors are using an old act
And how it's affecting drug CEOs

At a Families of Addicts meeting, fentanyl test strips are made available for purchase to detect the presence of fentanyl in street purchased drugs in Dayton, Ohio. (Caroline Brehman/CQ Roll Call)

As the effects of the opioid crisis are felt across the country, federal prosecutors are taking action and prosecuting CEOs of pharmaceutical companies. The Controlled Substance Act is one of their most novel weapons. 

House brief on Trump’s ‘disdain’ kicks off what could be messy two weeks
Cases in D.C., New Orleans showcase tussle between branches of government

House Oversight and Reform chairman Elijah Cummings is leading a House effort to subpoena President Donald Trump’s financial records. (Bill Clark/CQ Roll Call file photo)

The House told a federal appeals court Monday that President Donald Trump has “disdain” for congressional oversight ahead of action next week on the House’s efforts to subpoena his financial records from accounting firm Mazars USA. The brief sets the stage for what could be a messy couple of weeks legally on fights between Congress and the administration. 

“Mr. Trump’s disdain for the constitutionally based role of Congress in carrying out oversight of the Executive Branch, and for the specific investigations of the Oversight Committee at issue here, is not a basis for this Court to reverse the district court’s holding that the subpoena is valid and enforceable,” the brief stated.

Odd bedfellows share concerns over Pelosi drug plan
Conservatives and progressives wary of drug price arbitration, but for different reasons

Speaker of the House Nancy Pelosi, D-Calif., is developing a drug price plan that focuses on drug price arbitration. (Photo By Bill Clark/CQ Roll Call)